GLP1R and Obesity: Despite the absence of data detailing the use of these newer agents after bariatric surgery, the existing GLP-1-RA data in this setting and the substantial weight loss seen in non-surgical patients with obesity using semaglutide 2.4mg and tirzepatide suggest that these agents will likely provide more post-operative weight loss than prior GLP-1-RAs.